Prognostic Role of p53 Immunohistochemical Status in invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors
CONCLUSIONS: p53 IHC expression affects survival and, thus can be a valuable tool in the management of patients with HR-positive/Her2-negative breast cancer.PMID:37995311 | DOI:10.1093/oncolo/oyad309 (Source: The Oncologist)
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Gerti Dajti Margherita Serra Giovanni Cisternino Claudio Ceccarelli Alice Pellegrini Marica Melina Antonio De Leo Donatella Santini Mario Taffurelli Simone Zanotti Source Type: research

Head and Neck Squamous Cell Carcinoma of Unknown Primary: A Diagnostic Work-Up
This article seeks to consolidate contemporary strategies used to identify the primary tumor site of an unknown primary head and neck squamous cell carcinoma and offer recommendations based on current literature review.PMID:37995312 | DOI:10.1093/oncolo/oyad311 (Source: The Oncologist)
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Meenakkshy Manoharan Noah S Kalman Guilherme Rabinowits Source Type: research

Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study
CONCLUSIONS: Efficacy and safety of T-DXd were confirmed in an unselected real-world population of HER2+ mBC. These results are consistent with the results of known findings, and no new safety concerns were reported.PMID:37995313 | DOI:10.1093/oncolo/oyad308 (Source: The Oncologist)
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Andrea Botticelli Roberta Caputo Simone Scagnoli Simona Pisegna Michelino De Laurentiis Giuseppe Curigliano Matteo Lambertini Francesco Pantano Antonella Palazzo Ida Paris Claudio Vernieri Beatrice Tedesco Marianna Giampaglia Michela Palleschi Zelmira Bal Source Type: research

Clinical and Genotypic Insights Into Higher Prevalence of Palbociclib Associated Neutropenia in Asian Patients
CONCLUSION: Our retrospective analysis of real world palbociclib use reveals an association with grade 3/4 neutropenia with better outcome and early neutropenia nadir with worse outcome. Our findings of Asian specific SNPs support a predisposition toward profound and prevalent neutropenia in Asian patients under CDK4/6i. We also report the first pharmacokinetics analysis on a patient with peritoneal dialysis receiving CDK4/6i. In summary, our study provides novel clinical and genotypic insights into CDK4/6i associated neutropenia.PMID:37995303 | DOI:10.1093/oncolo/oyad304 (Source: The Oncologist)
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Jiun-I Lai Ting-Hao Kuo Kuan-Jung Huang Laura Min Xuan Chai Mei-Hsuan Lee Chun-Yu Liu Yi-Fang Tsai Chi-Cheng Huang Ling-Ming Tseng Cheng-Chih Hsu Ta-Chung Chao Source Type: research

Hydration Methods for Cisplatin Containing Chemotherapy: A Systematic Review
CONCLUSION: The hydration scheme of cisplatin should be short and consist of a relatively small amount of volume. The scheme should include mannitol and magnesium supplementation. Head-to-head studies are needed to investigate the safety of furosemide compared with mannitol and the dose of mannitol and magnesium.PMID:37995306 | DOI:10.1093/oncolo/oyad297 (Source: The Oncologist)
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Charlotte Sikking Kelly L Niggebrugge-Mentink A S Elise van der Sman Roefke H P Smit Esther W Bouman-Wammes Marieke M Beex-Oosterhuis Charlotte van Kesteren Source Type: research

Perspectives on the Treatment of Multiple Myeloma
Oncologist. 2023 Nov 23:oyad306. doi: 10.1093/oncolo/oyad306. Online ahead of print.ABSTRACTThe treatment of multiple myeloma has evolved significantly over the past few decades with the development of novel therapeutics. The introduction of proteasome inhibitors, immunomodulatory drugs, monoclonal antibodies, and high-dose chemotherapy followed by hematopoietic stem cell transplantation has led to improved response rates and survival outcomes. The use of bispecific antibodies and chimeric antigen receptor T-cell therapy is currently under study, and early results are showing promise. Although outcomes for patients with MM...
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Abdul Rafae Frits van Rhee Samer Al Hadidi Source Type: research

Patient-Reported Outcomes of Accelerated Aging: A Novel Approach to Investigate Second Cancer Risk in Adolescent and Young Adult (18-39 Years) Cancer Survivors
CONCLUSION: AYAs with a higher burden of accelerated aging were more likely to develop a second cancer. Validation of the clinical indicators and how to best capture them is needed to improve (early) detection of AYAs at high risk of developing second cancer.PMID:37995309 | DOI:10.1093/oncolo/oyad307 (Source: The Oncologist)
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Dani ël J van der Meer Susan Zevenbergen Carla Vlooswijk Rhod é M Bijlsma Suzanne E J Kaal Jan Martijn Kerst Jacqueline M Tromp Monique E M M Bos Tom van der Hulle Roy I Lalisang Janine Nuver Mathilde C M Kouwenhoven Winette T A van der Graaf Olga Husso Source Type: research

Prognostic Role of p53 Immunohistochemical Status in invasive Breast Cancer. A Retrospective Review of 1387 Cases With Luminal-Like/Her2 Negative Breast Tumors
CONCLUSIONS: p53 IHC expression affects survival and, thus can be a valuable tool in the management of patients with HR-positive/Her2-negative breast cancer.PMID:37995311 | DOI:10.1093/oncolo/oyad309 (Source: The Oncologist)
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Gerti Dajti Margherita Serra Giovanni Cisternino Claudio Ceccarelli Alice Pellegrini Marica Melina Antonio De Leo Donatella Santini Mario Taffurelli Simone Zanotti Source Type: research

Head and Neck Squamous Cell Carcinoma of Unknown Primary: A Diagnostic Work-Up
This article seeks to consolidate contemporary strategies used to identify the primary tumor site of an unknown primary head and neck squamous cell carcinoma and offer recommendations based on current literature review.PMID:37995312 | DOI:10.1093/oncolo/oyad311 (Source: The Oncologist)
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Meenakkshy Manoharan Noah S Kalman Guilherme Rabinowits Source Type: research

Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study
CONCLUSIONS: Efficacy and safety of T-DXd were confirmed in an unselected real-world population of HER2+ mBC. These results are consistent with the results of known findings, and no new safety concerns were reported.PMID:37995313 | DOI:10.1093/oncolo/oyad308 (Source: The Oncologist)
Source: The Oncologist - November 23, 2023 Category: Cancer & Oncology Authors: Andrea Botticelli Roberta Caputo Simone Scagnoli Simona Pisegna Michelino De Laurentiis Giuseppe Curigliano Matteo Lambertini Francesco Pantano Antonella Palazzo Ida Paris Claudio Vernieri Beatrice Tedesco Marianna Giampaglia Michela Palleschi Zelmira Bal Source Type: research

Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics
CONCLUSION: Prognostic models derived from the combination of clinicopathological features and peripheral blood indices, such as NLR, represent attractive markers mainly because they are easily detectable and applicable in daily clinical practice. More comprehensive prospective studies are needed to unveil their actual effectiveness.PMID:37971409 | DOI:10.1093/oncolo/oyad303 (Source: The Oncologist)
Source: The Oncologist - November 16, 2023 Category: Cancer & Oncology Authors: Sara Socorro Faria Diana Giannarelli Vladmir Claudio Cordeiro de Lima Sumadi Luckman Anwar Chiara Casadei Ugo De Giorgi Gabriele Madonna Paolo Antonio Ascierto Rossana Veronica Mendoza L ópez Roger Chammas Mariaelena Capone Source Type: research

The Use of Wearable Devices in Oncology Patients: A Systematic Review
CONCLUSION: Wearable devices may provide valuable data for the purposes of treatment monitoring, prognostication, and rehabilitation. Future studies should investigate live-time monitoring of collected data, which may facilitate directed interventions.PMID:37971410 | DOI:10.1093/oncolo/oyad305 (Source: The Oncologist)
Source: The Oncologist - November 16, 2023 Category: Cancer & Oncology Authors: Ronald Chow Hannah Drkulec James H B Im Jane Tsai Abdulwadud Nafees Swetlana Kumar Tristan Hou Rouhi Fazelzad Natasha B Leighl Monika Krzyzanowska Philip Wong Srinivas Raman Source Type: research

Clinical Predictors of Survival in Patients With BRAFV600-Mutated Metastatic Melanoma Treated With Combined BRAF and MEK Inhibitors After Immune Checkpoint Inhibitors
Oncologist. 2023 Nov 16:oyad300. doi: 10.1093/oncolo/oyad300. Online ahead of print.ABSTRACTProspective and between trial comparisons indicate that first-line treatment with immune checkpoint inhibitors improves survival outcomes compared to first-line therapy with combined BRAF and MEK inhibitors in metastatic melanoma containing BRAFV600E/K mutations. Long-term outcomes for BRAF/MEK inhibition after progression on immunotherapy have not been reported. Moreover, clinical variables associated with outcome from treatment with combined BRAF/MEK inhibition were previously identified in the first-line setting but have not been...
Source: The Oncologist - November 16, 2023 Category: Cancer & Oncology Authors: Adriana M Kahn Curtis J Perry Katrina Etts Harriet Kluger Mario Sznol Source Type: research

Association of Neutrophil-to-Lymphocyte Ratio and Absolute Lymphocyte Count With Clinical Outcomes in Advanced Breast Cancer in the MONARCH 2 Trial
CONCLUSION: Baseline NLR was independently prognostic of PFS and OS. Low-baseline NLR was associated with numerically better efficacy outcomes, but the benefit of adding abemaciclib to fulvestrant was similar irrespective of baseline NLR status.PMID:37971418 | DOI:10.1093/oncolo/oyad301 (Source: The Oncologist)
Source: The Oncologist - November 16, 2023 Category: Cancer & Oncology Authors: Eriko Tokunaga Yasuo Miyoshi Koji Dozono Tsutomu Kawaguchi Masakazu Toi Source Type: research

Development of a Prognostic Model for Early Breast Cancer Integrating Neutrophil to Lymphocyte Ratio and Clinical-Pathological Characteristics
CONCLUSION: Prognostic models derived from the combination of clinicopathological features and peripheral blood indices, such as NLR, represent attractive markers mainly because they are easily detectable and applicable in daily clinical practice. More comprehensive prospective studies are needed to unveil their actual effectiveness.PMID:37971409 | DOI:10.1093/oncolo/oyad303 (Source: The Oncologist)
Source: The Oncologist - November 16, 2023 Category: Cancer & Oncology Authors: Sara Socorro Faria Diana Giannarelli Vladmir Claudio Cordeiro de Lima Sumadi Luckman Anwar Chiara Casadei Ugo De Giorgi Gabriele Madonna Paolo Antonio Ascierto Rossana Veronica Mendoza L ópez Roger Chammas Mariaelena Capone Source Type: research